News publication
Everything we hold that bionity.com published.
Every article we hold from bionity.com.
Australian chronic-pain drug developer Spinifex Pharmaceuticals has agreed to be bought by Novartis for US$200 million upfront plus milestone payments; the piece recalls its 2005, 2008 and 2014 venture rounds.
Under GBS Ventures ·leads this story in the feed
Fibrotech Therapeutics raised $3 million in Series A backing from Brandon Capital-managed funds MRCF, BBF1 IIF and Uniseed to advance fibrosis drug FT011 through Phase Ib trials.
Deals recorded from bionity.com's coverage. A round is listed once, however many of their articles mention it.
| Company | Stage | Announced | Amount | Investors |
|---|---|---|---|---|
| Spinifex Pharmaceuticals | Series C | 13 May 2014 | $45m | |
| Fibrotech | Series A | 10 Feb 2009 | $3m | |
| Spinifex Pharmaceuticals | Unnamed stage | Jul 2005 | $3.2m |
Companies named in bionity.com's articles, most-covered first.
Investors named in bionity.com's articles, most-covered first.
| Investor | What it does | Articles |
|---|---|---|
| BBF1 IIF | 1 | |
| Brandon Capital | 1 | |
| Canaan Partners | 1 | |
| GBS Venture Partners Ltd. | 1 | |
| Novo Ventures | 1 | |
| UniQuest | 1 | |
| Uniseed | Venture fund backing early-stage deep tech and life science companies | 2 |